drugset
Drugs / STA-1
last change Dec 2018 re-read 2 minutes ago

STA-1

also known as Cistanche tubulosa
Developed for
vascular dementia · Alzheimer disease
Investigated by
Sinphar Pharmaceutical Co., Ltd

Trials 1 · a red edge is where a trial was stopped

today NCT01475578 · Ph 2
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01475578 Mar → Oct 2002 vascular dementia Sinphar Pharmaceutical Co., Ltd Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01255046 Comparator Dec 2015 → Dec 2018 Alzheimer disease Sinphar Pharmaceutical Co., Ltd Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as STA-1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01475578 ↗
1

NCT01255046 ↗
Known as Cistanche tubulosa “STA-1 capsule (Cistanche tubulosa), 2 capsules/time, 3 times/day, orally” NCT01475578 ↗
Route Oral “STA-1 capsule (manufactured by Sinphar Tian-Li (Hangzhou) Pharm. Co., Ltd.; Batch number: 020121), 2 capsules/time, 3 times/day, orally” NCT01475578 ↗